Soluble Terminal Complement Complex (sC5b-9) antibody

Catalog No. ABIN181111

This Mouse Monoclonal antibody specifically detects in FACS, IHC (fro), WB and EIA. It exhibits reactivity toward Human.

Quick Overview for Soluble Terminal Complement Complex (sC5b-9) antibody (ABIN181111)

Target: Soluble Terminal Complement Complex (sC5b-9)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Western Blotting (WB), Enzyme Immunoassay (EIA)

Clone: 3R2-0

Product Details

Characteristics: Synonyms: Terminal complement complex, Membrane attack complex

Purification: Affinity Chromatography on Protein A

Isotype: IgG2b

Application Details

Application Notes: ELISA. Western Blot. Flow Cytometry. Immunohistochemistry on frozen sections. Recommended Positive Control: Kidney from post streptoccal glomerulonephritis patients.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: Borate buffered saline, pH 8.4 containing 0.09 % Sodium Azide as preservative

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Expiry Date: 12 months

Target Details

Target: Soluble Terminal Complement Complex (sC5b-9)

Alternative Name: Complement SC5b-9 (TCC / MAC)

Background: Both the classical and alternative complement pathways result in the formation of the cytolysis inducing C5b-9 complex. This complex is composed of 190 kDa C5b which is bound to cells via 71 kDa C9. Sublytic assembly of C5b-9 on plasma membranes induces cell cycle activation and survival. The binding of C5b-9 to the 75 kDa S-protein (or vitronectin) in the fluid phase prevents C5b-9 from assembling on the plasma membrane, deactivating it and forming the SC5b-9 complex. SC5b-9 is stable in vitro and is therefore a reliable indicator of terminal complement pathway activation.Synonyms: Membrane attack complex, Terminal complement complex